Excited to share out latest work, out this week in @NatureGenet . In this study, we using CRISPR screens to explore how sensing inflammatory cytokines exposes new tumor-intrinsic dependencies. @broadinstitute @MGBResearchNews nature.com/articles/s41588-0…

Important Request for Information (RFI) from @NIH “Proposal to Cap the Number of Simultaneous Research Project Grants per Principal Investigator to Support More Researchers and Maximize Scientific Productivity and Innovation” grants.nih.gov/grants/guide/… Some suggested caps & impact:

Here’s our latest, we explored tumor B-cell infiltration in advanced urothelial carcinoma. Exciting collaboration with @OncoBellmunt Congrats to leading authors @KonradStawiski @PereraBel #BladderCancer #Bcells #TLS #MIBC

Another major advance vs cancer! @ASCO #ASCO26 Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda) ascopubs.org/doi/10.1200/JCO…

$3.1B! Congrats @brian_armstrong Epigenetic restoration is sure heating up

Meteor explodes off Massachusetts coast, causing loud boom, meteorologist confirms cbsnews.com/boston/news/mass…

Very excited to share an amazing body of work now out in Nature Biotechnology! For many years, the field of cancer immunology has recognized that immune-stimulatory dendritic cells, in particular cDC1, sit at the center of productive anti-tumor immunity. This is well conserved between mechanistic mouse models and humans, and high resolution single cell RNA seq studies have confirmed these cell states in a broad range of cancers. These cells sit at the core of controlling and facilitating T cell responses and tumor recognition, illustrating how DCs “shepherd” T cells across their lifecycle. These T: DC interactions lie at the center of the Cancer Immunity Cycle. Yet, so far, we only have efficient methods to push on T cells for immunotherapy. Boosting DC responses has been more difficult where treatments need to more carefully balance the toxicity associated with immune activation and efficacy. These concerns, balancing toxicity and efficacy, have led to significant challenges in drug development Here, we present a new approach enabled by catalytic advances in RNA therapeutics, where information gleaned from single-cell RNA seq cell states can be programmed into therapeutics to remodel the immune environment. We find that mRNA encoding cDC1-related factors such as interferon regulatory factor 8 (IRF8) and the NFkB-inducing kinase (NIK) can activate antigen presentation and trigger inflammation of tumors by T cells, leading to tumor-immune rejection. Notably, sustained expression of IRF8 is needed for maintaining cDC1 lineage identity, and elegant prior studies demonstrate that enforced IRF8 expression can reprogram diverse cell types into cDC1-like cells. Likewise, we had previously identified NIK expression within IL-12-producing tumor DCs, and others showed that NIK deficiency impaired IL-12 production and the ability to stimulate CD8 T cell responses. NIK lies downstream of CD40-based licensing, which is an essential step towards generating functional CD8 T cells. Here, we show that the application of these immune remodeling mRNAs (IR-mRNAs; either IRF8 or NIK) can synthetically activate antigen presentation and boost DC responses, triggering anti-tumor immunity. These IR-mRNAs shape the tumor microenvironment to be receptive to T cells, encouraging their accumulation and activity, further showing how DCs “shepherd” T cell responses. These can turn immune “cold” tumors “hot” and responsive to immune checkpoint blockade therapies. Perhaps the most fascinating aspect of these studies is when IR-mRNA is delivered alongside antigen in vaccination settings. We find that robust CD8 T cell responses are generated with IR-mRNA encoded immune adjuvants. This fits with the role of IRF8 and NIK supporting cDC1 responses, and raises the potential for a new class of cDC1-oriented immune therapeutics. This was all part of an amazing collaboration between the Anderson Lab at MIT Koch Institute for Integrative Cancer Research and the Center for Systems Biology at Massachusetts General Hospital/Harvard Medical School. @kochinstitute @MGHPathology @MGHCSB @MGBResearchNews #cancer #immunotherapy #vaccines #dendritic_cells #myeloid Extra kudos to the lead authors, @akashh_gupta and @Das_Riddha now at @UHEngineering The Article @NatureBiotech can be found here: nature.com/articles/s41587-0… Lay Summaries can be found here: news.mit.edu/2026/new-approa… ; massgeneralbrigham.org/en/ab…

Thanks @MassGenBrigham for highlighting our study in @NatureBiotech. We discussed the story behind our study, its real-world implications for patients, and how our approach could help make therapy-resistant tumors more visible to the immune system. Enjoy reading the Q&A!

A new mRNA strategy by @MassGenBrigham researchers turns "cold" tumors "hot" Read more, published in @NatureBiotech: massgeneralbrigham.org/en/ab… doi.org/10.1038/s41587-026-0… @WeisslederLab @csgarrix @MGHCSB @Das_Riddha

Realizing the potential of agonistic antibody immunotherapy nature.com/articles/s41573-0… rdcu.be/fjzZk This new Review discusses progress with agonist antibodies to treat autoimmune diseases and cancer, as well as approaches to addressing challenges in their development

Very excited to get this new work by Shin Ngiow up on #bioRxiv. We may be blocking PD-1 too long causing detrimental effects on Tpex cells. A drug holiday approach may be beneficial. Also some cool new Tpex biology here. #immunopharmacology biorxiv.org/content/10.64898…

@biorxivpreprint IL-12 is preferentially released at synapses formed with T cells displaying higher T cell receptor affinity, providing a mechanism for selection of the most potent T cell @uppsalauni doi.org/10.64898/2026.05.13.… 🇸🇪

Researchers led by Drs. Tanner Johanns, Niranjan Sardesai, and @GavinPDunn have shown that the personalized #DNAVaccine GNOS-PV01 safely triggers anti-tumor immune responses in #glioblastoma patients and shows promising early survival benefits in a phase 1 clinical trial. 🧬💉 Read the @NatureCancer study: go.nature.com/4dEQdLP

A new approach to cancer vaccination yields more powerful T cells #NBTintheNews news.mit.edu/2026/new-approa…

An innovation taking mRNA-nanoparticle cancer vaccines to the next level for potency and durability @NatureBiotech nature.com/articles/s41587-0…

Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models go.nature.com/42td2fh

Thrilled to share our @NatureBiotech paper using mRNAs that generate stronger and durable T cell responses by driving DC maturation and activation. This work highlights how defined immune-signaling pathways, paired with controlled delivery, can shape potent therapeutic immunity.

Thrilled to share that a major work from my postdoc is now published @NatureBiotech on #mRNA encoding immune-regulatory signals for #cancer #immunotherapy! Amazing collaboration between @kochinstitute and @MGHCSB, @MassGenBrigham. nature.com/articles/s41587-0…

Online now: Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy dlvr.it/TSCfRY